Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RX-5902||Supinoxin||CTNNB1 Inhibitor 26||Supinoxin (RX-5902) binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741, PMID: 31488700).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||RX-5902||Phase I||Actionable||In a Phase I trial, RX-5902 treatment resulted in stable disease in 43% (15/35) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P; NCT02003092).||detail...|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||RX-5902||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Supinoxin (RX-5902) decreased nuclear beta-catenin and Mcl-1 expression, induced cell cycle arrest and apoptosis in triple-receptor negative breast cancer cell lines in culture, led to tumor growth inhibition in cell line xenograft and patient derived xenograft (PDX) models (PMID: 31488700).||31488700|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02003092||Phase I||RX-5902||RX-5902 Treatment of Subjects With Solid Tumors||Terminated||USA||0|